A risk-benefit assessment of pharmacological treatments for panic disorder

Drug Safety

Volumn 18, Issue 6, 1998, Pages 419-430

  Bennett, Jerry A ^a,b   Moioffer, Molly ^a   Stanton, Sean P ^a   Dwight, Megan ^a   Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANIMAL EXPERIMENT; ANTICHOLINERGIC EFFECT; ANXIETY; ATAXIA; CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG OVERDOSE; DYSPEPSIA; HEADACHE; HUMAN; INSOMNIA; MENTAL DISEASE; META ANALYSIS; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANIC; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; HUMANS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; PSYCHOTHERAPY; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; VALPROIC ACID;

EID: 0031863110     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818060-00003     Document Type: Review

References (92)

1. Myers JK, Weissman MM, Tischler GL, et al. Six month prevalence of psychiatric disorders in three communities: 1980-1982. Arch Gen Psychiatry 1984; 41: 959-67
2. Klein DV. Delineation of two drug responsive anxiety syndromes. Psychopharmacologia 1964; 5: 397-408
3. Klein DV. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967; 16: 118-26
4. Wilkerson G, Balestreri M, Ruggeri M, et al. Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines tor patients with panic disorders. Psychol Med 1991; 21: 991-8
5. Zitrin CM, Klein DF, Woerneer MG, et al. Treatment of phobias: I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40: 125-38
6. Klerman GL. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo: cross national collaborative panic study second phase investigators. Br J Psychiatry 1992; 160: 191-202
7. Den Boer JA, Westenberg HGM, Kamerbeck WDJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987; 2: 21-32
8. Hoffart A, Due-Madsen J, Land B, et al. Clomipramine in the treatment of agoraphobia in patients resistant to behavioral therapy. J Clin Psychiatry 1993; 54: 481-7
9. Fahy TH, O'Rourke D, Brophy J, et al. The Galway study of panic disorder I: clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 1942; 25: 63-76
10. Modigh K, Westberg P, Erickson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo controlled trial. J Clin Psychophamacol 1992; 12: 251-61
11. Bahhenger JC, Peterson GA, Laraia M, et al. A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response. In: Ballenger JC, editor. Biology of agoraphobia. Washington, DC: American Psychiatric Press, 1984: 28-63
12. Marks IM, Gray S, Cohen D, et al. Imipramine and brief therapist aided exposure in agoraphobics having self exposure homework. Arch Gen Psychiatry 1983; 40: 153-62
13. Nesse RM, Cameron OG, Curtis GC, et al. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 1984; 41: 771-6
14. Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992; 149: 1053-7
15. Clark DM, Salkovskis DM, Hackman A, et al. A comparison of cognitive therapy applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994; 164: 759-69
16. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Areh Gen Psychiatry 1992; 49: 318-23
17. Sheehan DV, Ballenger J, Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51-9
18. Keller MB, Lavori PW, Goldenberg IM, et al. Influence of depression on the treatment of panic disorder with imipramine. alprazolam, and placebo. J Affect Disord 1993; 28: 27-38
19. Schweizer H, Rickels K, Weiss S, et al. Maintenance drug treatment of panic disorder I: results of a prospective, placebo controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50: 51-60
20. Noyes R, Garvey MJ, Cook BL. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow up study. J Clin Psychiatry 1989; 50: 163-9
21. Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry 1991; 52 Suppl.: 18-23
22. Lydiard RB, Ballenger JC. Antidepressants in panic disorder and agoraphobia. J Affect Disord 1987; 13: 153-68
23. Sheehan DV. Tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics 1986; 27 Suppl. 11: 10-6
24. Balon R, Yeragani VK, Pohl R, et al. Changes in appetite and weight during Ihe pharmacological treatment of patients with panic disorder. Can J Psychiatry 1993; 38: 19-22
25. Louie AK, Lewis TB, Lannon RA. Use of low dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-8
26. Schatzberg AF, Ballenger JC. Decisions tor the clinician in the treatment of panic disorder: When to treat, which treatment to use, and how long to treat. J Clin Psychiatry 1991; 52 Suppl. 2: 26-31
27. Roy-Byrne P, Wingerson D, Cowley D, et al. Psychopharmacologic treatment of panic, generalized anxiety disorder and social phobia. Psychiatry Clin North Am 1993; 16: 719-35
28. Caplan JD, Gorman JM, Klein DF. Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacol 1992; 6: 189-200
29. Den Boer JA, Westenberg HG. Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study wiith fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74
30. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321-6
31. Christiansen PE, Judge R, Ohrstrom JK. A double-blind, placebo-controlled parallel group study of paroxetine in combination with psychotherapy in treatment of patients with panic disorder (DSM III-R) [abstract]. 31st Annual Meeting of American College of Neuropsychopharmacology: 1992 Dec 14-18; San Juan, Puerto Rico: 149
32. Goddurd AW, Woods SW, Sholomskas DE, et al. Effects of serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993; 48: 119-33
33. Rickels K, Schweizer EE. Benzodiazepines for the treatment of panic attacks: A new look. Psychopharmacol Bull 1986; 22: 93-9
34. Jefferson WJ. Antidepressants in panic disorder. J Clin Psychiatry 1997; 58 Suppl. 2: 20-4
35. Marshall JR. Panic disorder: a treatment update. J Clin Psychiatry 1997; 57: 36-42
36. Black DW, Wesner R, Gabal J. The abrupt discontinuation of fluoxetine in patients with panic disorder. J Clin Psychiatry 1993; 54: 146-9
37. Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7: 329-32
38. Davidson JRT. Use of benzodiazepines in panic disorder. J Clin Psychiatry 1997; 58 Suppl.2: 26-8
39. McEvoy GK. AHFS Drug Information. Bethesda (MD): Benzodiazepines. 1955: 1581-606
40. Uhlenhuth EH, Matuzas W, Glass RM, et al. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17: 261-70
41. Herman JB, Rosenbaum JF, Brotman AW. The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 1987; 7: 175-8
42. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69-76
43. Tesar GE, Rosenbaum JF. Successful use of clonazepam in patients with treatment-resistant panic disorder. J Nerv Ment Dis 1986; 174: 477-82
44. Spier SA, Tesar GE, Rosenhaum JF, et al. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986; 47: 238-42
45. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry 1987; 48 (10 Suppl.): 4-9
46. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder: pathophysiology and drug treatment. Drugs 1995; 49: 328-44
47. Chouinard G, Labonte A, Fontaine R, et al. New concepts in benzodiazepine therapy: rebound anxiety and new indications for more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 669-73
48. Fontaine R, Chouinard G. Anti-panic effect of clonazepam [letter]. Am J Psychiatry 1984; 141: 149
49. Beaudry P, Fontaine R, Chouinard G, et al. Clonazepam in the treatment of patients with recurrent panic attacks. J Clin Psychiatry 1986; 47: 83-5
50. 2 inhalation-provoked panic in a patient with panic disorder. J Clin Psychiatry 1986; 47: 475-6
51. Pollack MH, Tesar GE, Rosenhaum JF, et al. Clonazepam in the treatment of panic disorder and agoraphobia: A one-year follow-up. J Clin Psychopharmacol 1986; 6: 302-4
52. Tesar GE, Rosenbaum JF, Pollack MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987; 48 (19 Suppl.): 16-9
53. Uhde TW, Boulenger JP, Roy-Byrne, et al. Longitudinal course of panic disorder: clinical and biological considerations. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 39-51
54. Breier A, Charney DS, Heninger GR. The diagnostic validity of anxiety disorders and their relationship to depressive illness. Am J Psychiatry 1985; 142: 787-97
55. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia: I: Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988; 81: 830-1
56. Nikaido AM, Ellinwood EH, Heatherly DG, et al. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology 1990; 100: 90-7
57. Lader MH; Ron M, Petursson H. Computerized axial brain tomographic studies following long-term use of benzodiazepines. Psychol Med 1987; 17: 775-7
58. Roy-Byrne PP, Cowley DS, Greenblatt D, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990; 7: 534-8
59. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive lest performance. Psychopharmacology 1986; 88: 426-33
60. DSM IV. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association. 1994 Jul
61. Ciraulo DA, Barnhill JC, Ciraulo AM, et al. Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study. Am J Psychiatry 1989; 146: 1333-5
62. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: discontinuation effects. Arch Gen Psychiatry 1988; 45: 429-36
63. Pecknold JC. Discontinuation studies: short-term and long-term. Panic and anxiety: a decade ot progress: 1990 Jun 19-22; Geneva
64. Woods SW, Nagy LM, Koleszar AS, et al. Controlled trial of alprazolam supplementation during imipramine treatment of panis disorder. J Clin Psychiatry 1992; 12: 32-8
65. Sergant W. The treatment of anxiety states and atypical depression by the monoamine oxidase inhibitor drugs. J Neuropsychiatry 1962; 3: 96-103
66. Norman TR, Burrows GD. Monamine oxiduse, monoamine oxidase inhibitors, and panic disorder. J Neural Transm 1989; 28: 53-63
67. West ED, Dally PJ. Effects of iproniazid depressive syndromes. BMJ 1959: 1: 1491-4
68. Tyres P, Candy D, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 1973; 32: 237-54.
69. Ballenger JC, Sheehan DV, Jacobsen G, et al. Antidepressant treatment of severe phobic anxiety [abstract]. Abstracts of Scientific Proceedings at the 130th Annual Meeting of the American Psychiatric Association: 1977 May 2-6; Toronto, C'anada
70. Mountjoy CQ, Roth M, Gartside RF. A clinical trial of phenelzine in anxiety, depressive and phobic neuroses. Br J Psychiatry 1977; 131: 486-92
71. Solyom C, Solyom L, LaPierre Y, et al. Phenelzine and exposure in the treatment of phobias. Biol Psychiatry 1981; 16: 239-47
72. Laird LK, Benefield WH. Mood disorders I: major depressive disorders. In: Young LY, Koda-Kimble MA, editors. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics, 1995; 76.1-76.24
73. Ballenger JC, Lydiard RB, Turner SM. Panic disorder and agoraphobia. In: Gabbard GO, editor. Treatment of psychiatric disorders. 2nd ed. Washington, DC: American Psychiatric Press, Inc, 1995; 1421-52
74. Rimmer EM, Richens A. An update on sodium valproate. Pharmacotherapy 1985; 5: 171-84
75. Sanger DJ. Mini review: GABA and the behavioral effects of anxiolytic drugs. Life Sci 1985; 16: 1503-13
76. Shephard RA. Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action. Life Sci 1987; 40: 2429-36
77. Penfield W, Jasper H. Epilepsy and the functional anatomy of the human brain. Boston: Little Brown, 1954
78. Stern TA, Murray GB. Complex partial seizures presenting as a psychiatric illness. J Nerv Ment Dis 1984; 172: 625-7
79. Roy-Byrne PP. Anticonvulsants in anxiety and withdrawal syndromes: hypotheses lor future research. In: McElroy SL, Pope Jr HG, editors. Use of anticonvulsants in psychiatry: recent advances. Clifton (NJ): Oxford Health Care, 1988: 155-68
80. McElroy SL, Keck Jr PE, Laurence JL. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci 1991; 2: 212-1
81. Roberts JM, Malcolm R, Santos AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium [letter]. Am J Psychiatry 1994; 151: 1521
82. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990; 35: 248-50
83. Keck Jr PE, Taylor VE, Tugrul KC, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33: 542-6
84. Keck Jr PE, McElroy SL, Tugrul KC, et al. Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology 1993; 27: 150-3
85. Woodman CL, Noyes R, Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1944; 55: 134-6
86. Lum M, Fontaine R, Elie R, et al. Divalproex sodium antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 1990; 27: 164-5A
87. Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgements in dementia: implications for clinical research. Pyschopharmacol Bull 1992; 28: 425-32
88. Bruss GS, Gruenberg AM, Goldstein RD, et al. Hamilton anxiety rating scale interview guide: joint interview and test-re-test methods for interrater reliability. Psychiatry Res 1994; 53: 191-202
89. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 1973; 9: 13-28
90. Balon R, Petty F, Yergani VK, et al. Intravenous lactate decreases plasma GABA levels in man. Psychopharmacology 1993; 110: 368-70
91. Wood WD. An attempt to validate the psychoticism scale of the Brief Symptom Inventory. Br J Med Psychol 1982; 55: 367-73
92. Anon. Practical approaches to the treatment of panic disorder. J Clin Psychiatry 1996; 57: 45-52